by Raynovich Rod | Sep 24, 2013 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Life Science Sector at or Near YTD and All Time Highs Fidelity Fund (FBIOX) Outperform ETFs Over the past 3 years we reviewed how ETFs complement a biotechnology investment strategy and compared three of the largest and most liquid : FBT, IBB and XBI (see the...
by Raynovich Rod | Sep 16, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools
“Yellen” Effect Boosts Markets-FED Policies Clarified With Larry Summers dropping out as a likely candidate for FED Chairman the market may be assured of a continuation of current FED policy. The market sees no surprises in Janet Yellen who is a...
by Raynovich Rod | Sep 11, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools
NASDAQ Struggling As AAPL Down 5%–IBB ($205.36) off 0.4% Near All Time High of $207.78 The market is trying to continue its resilience since the hits on Syria were postponed pending Russian efforts with Assad. The 10 Year Treasury had an A+ offering at...
by Raynovich Rod | Sep 4, 2013 | 2024-25 Life Science Portfolios, Biopharmaceuticals
M&A Moves Down the Food Chain: Otsuka to Buy Astex for ~$900M Astex Pharmaceuticals (ASTX $8.22) has been on our focus list since 12/27/11 at $1.63 and today the stock is up 23% on buy-out news as Otsuka seeks cancer drug pipeline. Coming soon, a comparison of...
by Raynovich Rod | Sep 3, 2013 | Biopharmaceuticals
(Published this am in Seeking Alpha) Onyx Pharmaceuticals (ONXX) $10.4B Buy-Out Fuels Speculative Deal Lists We have written extensively on the life science bull market and its underpinnings: cheap money, scientific breakthroughs, sales growth and of course, M&A....
by Raynovich Rod | Aug 28, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
But Uncertainty Clouds Intermediate Term Economic Outlook: Oil prices, Emerging Markets, Russia and the FED Concerns about another Middle East war and a spike in oil prices waned a bit today but many “undertoads” remain such as weak economic data, taper...
by Raynovich Rod | Aug 26, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Life science stocks resumed their upward trajectory today with major ETFs (FBT,IBB,XBI) up over 2% and a green screen for the sector. Mid-cap biopharma stocks are strong once again. The IBB hit an August low of $187 on August 19 after a high in early August near $201....
by Raynovich Rod | Aug 21, 2013 | Biopharmaceuticals, Macro
Very Strange Whipsaw Day Who is in charge of this market, humans or computers? Earlier: My biopharma screen has gone green. Maybe “taper light” scenario means buy biotech as macro and interest rates are not affected. More later but NASDAQ reversal...
by Raynovich Rod | Aug 18, 2013 | Biopharmaceuticals, Macro
Tempering, Tapering and Transition A mild sell-off shifted momentum to the bears last week as countercurrents and seasonality comes into play. Heavy vacations in August transition to Labor Day weekend, Jewish holidays then a pick up in trading by mid-September. Here...
by Raynovich Rod | Aug 15, 2013 | Biopharmaceuticals, Macro
Biotech Sector Momentum Quits-IBB at Support Level of $189 NASDAQ Off 1.73% to 3605 Have fund managers raised cash and gone on vacation? Moreover many weaker sectors have become leaders like gold, silver,materials and energy. Walmart and Cisco are leading the way...
